Length of Anticoagulation in Provoked Venous Thromboembolism: A Multicenter Study of How Real-World Practice Mirrors Guideline Recommendations.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
11 2022
Historique:
pubmed: 27 10 2022
medline: 3 11 2022
entrez: 26 10 2022
Statut: ppublish

Résumé

Background For more than a decade, guidelines have recommended a limited 3 months of anticoagulation for the treatment of provoked venous thromboembolism (VTE). How closely real-world practice follows guideline recommendations is not well described. Methods and Results In our multicenter, retrospective cohort study, we evaluated trends in anticoagulation duration for patients enrolled in the MAQI

Identifiants

pubmed: 36285782
doi: 10.1161/JAHA.122.025471
pmc: PMC9673630
doi:

Substances chimiques

Warfarin 5Q7ZVV76EI
Anticoagulants 0

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e025471

Subventions

Organisme : NHLBI NIH HHS
ID : T35 HL007690
Pays : United States

Références

J Thromb Haemost. 2015 Nov;13(11):2012-20
pubmed: 26356595
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Pharm Pract (Granada). 2019 Jul-Sep;17(3):1539
pubmed: 31592294
N Engl J Med. 2013 Feb 21;368(8):699-708
pubmed: 23216615
Thromb Haemost. 2019 Aug;119(8):1365-1372
pubmed: 31183844
J Thromb Thrombolysis. 2013 Jan;35(1):10-4
pubmed: 22797905
N Engl J Med. 2017 Mar 30;376(13):1211-1222
pubmed: 28316279
Am J Surg. 2010 Jan;199(1 Suppl):S3-10
pubmed: 20103082
Blood. 2014 Sep 18;124(12):1968-75
pubmed: 24963045
Ann Intern Med. 2010 May 4;152(9):578-89
pubmed: 20439576
Chest. 2008 Jun;133(6 Suppl):454S-545S
pubmed: 18574272
Am J Med. 2015 Dec;128(12):1300-5.e2
pubmed: 26144101
Chest. 2012 Feb;141(2 Suppl):e419S-e496S
pubmed: 22315268
Chest. 2021 Dec;160(6):e545-e608
pubmed: 34352278
Blood Adv. 2020 Oct 13;4(19):4693-4738
pubmed: 33007077

Auteurs

Elizabeth Joyce (E)

University of Michigan Medical School Ann Arbor MI.

Brian Haymart (B)

Michigan Medicine Frankel Cardiovascular Center Ann Arbor MI.

Xiaowen Kong (X)

Michigan Medicine Frankel Cardiovascular Center Ann Arbor MI.

Mona A Ali (MA)

Beaumont Hospital Royal Oak Royal Oak MI.

Mara Carrigan (M)

Michigan Medicine Frankel Cardiovascular Center Ann Arbor MI.

Scott Kaatz (S)

Henry Ford Hospital Detroit MI.

Vinay Shah (V)

Henry Ford Hospital Detroit MI.

Eva Kline-Rogers (E)

Michigan Medicine Frankel Cardiovascular Center Ann Arbor MI.

Jay Kozlowski (J)

Huron Valley-Sinai Hospital Commerce Township MI.

James B Froehlich (JB)

Michigan Medicine Frankel Cardiovascular Center Ann Arbor MI.

Geoffrey D Barnes (GD)

Michigan Medicine Frankel Cardiovascular Center Ann Arbor MI.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH